CN112971150A - Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof - Google Patents
Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN112971150A CN112971150A CN202110366079.XA CN202110366079A CN112971150A CN 112971150 A CN112971150 A CN 112971150A CN 202110366079 A CN202110366079 A CN 202110366079A CN 112971150 A CN112971150 A CN 112971150A
- Authority
- CN
- China
- Prior art keywords
- aminobutyric acid
- gamma
- freeze
- release tablet
- flash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 130
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 108010010803 Gelatin Proteins 0.000 claims abstract description 18
- 238000004108 freeze drying Methods 0.000 claims abstract description 18
- 239000008273 gelatin Substances 0.000 claims abstract description 18
- 229920000159 gelatin Polymers 0.000 claims abstract description 18
- 235000019322 gelatine Nutrition 0.000 claims abstract description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 18
- 239000004373 Pullulan Substances 0.000 claims abstract description 17
- 229920001218 Pullulan Polymers 0.000 claims abstract description 17
- 239000000853 adhesive Substances 0.000 claims abstract description 17
- 230000001070 adhesive effect Effects 0.000 claims abstract description 17
- 235000019423 pullulan Nutrition 0.000 claims abstract description 17
- 238000007710 freezing Methods 0.000 claims abstract description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 230000008014 freezing Effects 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 7
- 238000007872 degassing Methods 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- -1 gamma-aminobutyric acid saccharide Chemical class 0.000 claims description 2
- 238000009849 vacuum degassing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 5
- 238000005336 cracking Methods 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 20
- 229960001855 mannitol Drugs 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and a preparation method thereof. The unit dose of the freeze-dried flash-release tablet comprises 25mg of gamma-aminobutyric acid, 50-60mg of a framework supporting agent and 9.5-14.5mg of an adhesive; the skeletal support is selected from mannitol; the adhesive is composed of pullulan and gelatin, and the mass ratio of the pullulan to the gelatin is preferably 4.5:5.0-4.5: 10. The gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet prepared by the invention is formed by quick freezing, only a small amount of skeleton supporting agent and adhesive are used, the purity of the formula can be ensured to the maximum extent, and the adding amount of food auxiliary materials and additives is greatly reduced. The freeze-dried flash-release tablet prepared by optimizing the prescription and the process overcomes the problems of cracking and collapsing of the preparation in the freeze-drying process and in the inner package, and can effectively prolong the effective period of the product.
Description
Technical Field
The invention belongs to the field of food and health food, and relates to a gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and a preparation method thereof.
Background
Gamma-aminobutyric acid is a natural active ingredient, is also a non-protein amino acid, is widely distributed in animals and plants, contains seeds, rhizomes and tissue fluid of beans, ginseng, Chinese herbal medicines and the like, participates in various metabolic activities, and has high physiological activity. As early as 27.9.2009, the 2009 No. 12 bulletin of the Ministry of health has approved gamma-aminobutyric acid as a new resource food material, and allows for application to beverages, cocoa products, chocolate and chocolate products, candies, bakery products, and puffed foods.
At present, the research on the efficacy of gamma-aminobutyric acid at home and abroad is very deep, and as a novel special functional factor, the gamma-aminobutyric acid is widely applied to the fields of medicine, health care, feed, chemical industry and the like, and the physiological efficacy mainly comprises the following points:
1. tranquilizing nerve and resisting anxiety
It has been demonstrated by physicians that gamma-aminobutyric acid is an inhibitory transmitter of the central nervous system and is one of the most important neurotransmitters in brain tissue. It acts to reduce neuronal activity and prevent neuronal overheating, gamma aminobutyric acid binds to and activates anxiolytic brain receptors, and then acts synergistically with other substances to prevent anxiety-related information from reaching the brain signaling center.
A large number of researches prove that the gamma-aminobutyric acid can shorten the time of falling asleep, prolong the slow wave sleep II period and the fast eye movement sleep period and help a human body to fall asleep quickly.
2. Lowering blood pressure
The gamma-aminobutyric acid can act on the vasomotor center of the spinal cord, effectively promote the vasodilatation and achieve the aim of reducing the blood pressure. In the research on the traditional Chinese medicine astragalus, the most effective antihypertensive component is gamma-aminobutyric acid.
3. Treating diseases
Gamma-aminobutyric acid has special medicinal value, and is one of hot spots in recent years for treating epilepsy.
4. Reducing blood ammonia
In clinical medicine in China and researchers in Japan, it is also considered that gamma-aminobutyric acid can inhibit decarboxylation of glutamic acid to reduce blood ammonia. More glutamic acid is combined with ammonia to generate urea which is discharged out of the body, thereby eliminating ammonia toxicity and improving the liver function. The intake of gamma-aminobutyric acid can improve the activity of glucose phosphatase, make brain cells active vigorously, promote the metabolism of brain tissues, recover the functions of the brain cells and improve the nerve functions.
5. Promoting ethanol metabolism
After drinking 60ml whiskey after drinking gamma-aminobutyric acid, blood was sampled to measure the concentration of ethanol and acetaldehyde in blood, and the concentration of the latter was found to be significantly lower than that of the control group.
6. Others
The latest research shows that the gamma-aminobutyric acid also has the functions of preventing skin aging, improving lipid metabolism, preventing arteriosclerosis, efficiently losing weight and the like.
The mainstream products related to gamma-aminobutyric acid in the market at present are tablet candy, gel candy and the like, and for people taking gamma-aminobutyric acid for calming nerves and resisting anxiety to improve sleep, the defects of the dosage forms are that drinking water is needed during taking, and the supplement of water before sleep is high, so that the insomnia patients can get up at night and then fall asleep again difficultly. The gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet prepared by the freeze-drying flash-release technology does not need to be drunk and dissolved in the mouth when being taken, and the problem can be effectively solved.
These mainstream products also have a disadvantage in that a large amount of fillers, wetting agents, binders, disintegrants, lubricants, etc. are added in order to satisfy the tablet moldability, hardness, dissolution, etc., so that people have to take in a large amount of auxiliary materials and additives without any nutritional value while taking in effective gamma-aminobutyric acid. The freeze-drying flash release technology is quick-freezing molding, and only a small amount of a skeleton supporting agent and a bonding agent are added.
Disclosure of Invention
The invention aims to provide a gamma-aminobutyric acid saccharified sugar freeze-drying flash-release tablet and a preparation method thereof.
The gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet provided by the invention contains 25mg of gamma-aminobutyric acid, 50-60mg of a skeleton supporting agent and 9.5-14.5mg of an adhesive in unit dose.
Furthermore, the gamma-aminobutyric acid dissolved sugar-containing freeze-dried flash-release tablet can also comprise 1-2mg, specifically 2mg, of fructo-oligosaccharide in unit dose.
In the present invention, the backbone support is selected from mannitol; the content of mannitol in the unit dose of the gamma-aminobutyric acid saccharide-containing freeze-dried flash release tablet can be 50mg, 55mg or 60 mg.
In the invention, the adhesive consists of pullulan and gelatin, preferably, the mass ratio of the pullulan to the gelatin is 4.5:5.0-4.5: 10; specifically, it may be 4.5:5.0, 4.5:7.5 or 4.5: 10.
The invention also provides a preparation method of the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet.
The raw materials of the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet provided by the invention comprise the following substances in percentage by mass and volume (g/100 ml): 5 percent of gamma-aminobutyric acid, 10 to 12 percent of framework supporting agent, 1.9 to 2.9 percent of adhesive and the balance of purified water.
Wherein the matrix support is selected from mannitol; the adhesive is composed of pullulan and gelatin, and preferably, the mass ratio of the pullulan to the gelatin is 4.5:5.0-4.5: 10.
Furthermore, the raw materials also comprise 0.2 to 0.4 percent of fructo-oligosaccharide.
The preparation method of the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet provided by the invention comprises the following steps:
1) dissolving pullulan and gelatin in water to obtain a feed liquid (1);
2) adding fructo-oligosaccharide, mannitol and gamma-aminobutyric acid into the feed liquid (1), stirring to completely dissolve, and then supplementing the balance of water to obtain a feed liquid (2);
3) emulsifying the feed liquid (2);
4) injecting the emulsified material into a mold, quickly freezing, and freeze-drying to obtain the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet.
In the step 3), the emulsification is performed in an emulsifying machine, wherein the rotation speed of the emulsifying machine is 5000-15000rpm, specifically 10000 rpm; the emulsifying time is 5-30min, specifically 10 min.
In the step 3), the method further comprises a degassing step after emulsification, preferably, the degassing is vacuum degassing for 1-20min, preferably 2-10 min.
In the step 4), the mold is an aluminum-plastic bubble plate.
In the step 4), the quick-freezing conditions are as follows: and (3) quick-freezing temperature: the temperature is between 80 ℃ below zero and 100 ℃ below zero, and the time is 5 to 10 minutes, and the method specifically comprises the following steps: speed 10min at-100 ℃. The temperature of quick freezing is lower, the quick freezing time is shorter, and ice crystals formed in the preparation are finer, so that the preparation can be disintegrated in the oral cavity more quickly and has better taste.
In step 4), the freeze-drying curve of the freeze-drying is as follows: keeping the temperature at 35 ℃ below zero for 2-3 h; keeping the temperature of between 35 ℃ below zero and 25 ℃ below zero for 3 to 4 hours; keeping the temperature of between 25 ℃ below zero and 15 ℃ below zero for 1 to 2 hours; keeping the temperature of between 15 ℃ below zero and 10 ℃ below zero for 1 to 3 hours; keeping the temperature at-10 to 25 ℃ for 3 to 5 hours.
According to one embodiment of the invention, the lyophilization profile is: -35 ℃ for 180 minutes; raising the temperature to-25 ℃ at-35 ℃ for 180 minutes; raising the temperature to-15 ℃ at-25 ℃ for 120 minutes; raising the temperature to-10 ℃ at-15 ℃ for 120 minutes; -10 ℃ to 5 ℃ for 60 minutes; the temperature was raised to 25 ℃ for 180 minutes.
Compared with the prior art, the invention has the following beneficial technical effects:
the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet prepared by the invention is formed by quick freezing, only a small amount of skeleton supporting agent and adhesive are added, the purity of the formula can be ensured to the maximum extent, and the adding amount of food auxiliary materials and additives is greatly reduced. Taking a certain gamma-aminobutyric acid tablet candy product in the market as an example, each tablet weighs 700mg, wherein the tablet contains 150mg of gamma-aminobutyric acid, and other 550mg of gamma-aminobutyric acid tablet candy products are food auxiliary materials and additives; compared with the above product, the gamma-aminobutyric acid (150mg) with the same amount is ingested, and the amount of the ingested auxiliary materials and additives is reduced by 33%, so that the product is safer from the food safety perspective. In addition, the gamma-aminobutyric acid sugar-containing freeze-drying flash-release tablet prepared by the inventor through the prescription and process optimization overcomes the problems of cracking, collapse and sticking of the preparation in the freeze-drying process and in an inner package, and can effectively prolong the effective period of the product.
Detailed Description
The present invention will be further illustrated with reference to the following specific examples, but the present invention is not limited to the following examples. The method is a conventional method unless otherwise specified. The starting materials are commercially available from the open literature unless otherwise specified.
The gamma-aminobutyric acid used in the examples described below was purchased from Tianjin century Tianlong Biotech limited.
The fructooligosaccharides used in the examples described below were QHT-FOS-P95S (WL), a product of biological origin, Quantum Gaokou (China).
Pullulan used in the following examples was purchased from Pioneer 26384; mannitol was purchased from Shandong Tianli pharmaceutical Co., Ltd; gelatin was purchased from Beijing Hehuawei trade company, Inc., catalog number 120LB 8.
Preparation example
Example 1 preparation of lyophilized flash-release tablets containing gamma-aminobutyric acid and sugar
The prescription composition is as follows:
the preparation process comprises the following steps:
1. weighing 350ml of purified water, placing the purified water in a beaker, heating the purified water in a water bath at 50 ℃, weighing the pullulan and the gelatin in the prescription amount, placing the pullulan and the gelatin in the beaker, heating the purified water in the water bath, and stirring the pullulan and the gelatin by using a glass rod to completely dissolve the pullulan and the gelatin;
2. weighing fructo-oligosaccharide, mannitol and gamma-aminobutyric acid according to the formula amount, adding the fructo-oligosaccharide, mannitol and gamma-aminobutyric acid into the feed liquid (1), stirring until the fructo-oligosaccharide, mannitol and gamma-aminobutyric acid are completely dissolved, adding purified water, and fixing the volume to 500 ml;
3. emulsification and degassing: emulsifying the feed liquid (2) in an emulsifying machine at the rotation speed of 10000rpm for 10 minutes; the emulsified feed solution was degassed under vacuum for 10 minutes.
4. Filling: respectively filling the feed liquid (3) into the bubble holes of an aluminum-plastic bubble-cap plate at a concentration of 0.5 ml/piece;
5. quick-freezing: placing the bubble cap plate filled with the feed liquid into a liquid nitrogen tunnel at the temperature of 100 ℃ below zero for prefreezing for 10 minutes;
6. freeze-drying: transferring the pre-frozen bubble plate to a freeze dryer plate layer, and operating the following freeze drying curve: -35 ℃ for 180 minutes; raising the temperature to-25 ℃ at-35 ℃ for 180 minutes; raising the temperature to-15 ℃ at-25 ℃ for 120 minutes; raising the temperature to-10 ℃ at-15 ℃ for 120 minutes; -10 ℃ to 5 ℃ for 60 minutes; the temperature was raised to 25 ℃ for 180 minutes.
7. Sealing: and (4) taking the blister plate out of the freeze dryer, and coating, packaging and slitting on a sealing machine.
Example 2 preparation of lyophilized flash-release tablets containing gamma-aminobutyric acid and sugar
The prescription composition is as follows:
the preparation process comprises the following steps: the same as in example 1.
Example 3 preparation of lyophilized flash-release tablets containing gamma-aminobutyric acid and sugar
The prescription composition is as follows:
the preparation process comprises the following steps: the same as in example 1.
Example 4 preparation of lyophilized flash-release tablets containing gamma-aminobutyric acid and sugar
The prescription composition is as follows:
the preparation process comprises the following steps: the same as in example 1.
Comparative example 1 preparation of lyophilized flash-release tablet containing solubilized sugar of gamma-aminobutyric acid
The prescription composition is as follows:
the preparation process comprises the following steps: the same as in example 1.
Comparative example 2 preparation of lyophilized flash-release tablet containing solubilized sugar of gamma-aminobutyric acid
The prescription composition is as follows:
the preparation process comprises the following steps:
same as comparative example 1
Comparative example 3 preparation of lyophilized flash-release tablet containing solubilized sugar of gamma-aminobutyric acid
The prescription composition is as follows:
the preparation process comprises the following steps:
same as comparative example 1
Comparative example 4 preparation of lyophilized flash-release tablet containing solubilized sugar of gamma-aminobutyric acid
The prescription composition is as follows: same as example 1
The preparation process comprises the following steps: basically, the same as example 1, except that: the different quick-freezing conditions are as follows: and placing the bubble plate filled with the feed liquid into a low-temperature refrigerator at the temperature of 60 ℃ below zero for pre-freezing for 60 minutes.
Comparative example 5
The prescription composition is as follows: same as example 1
The preparation process comprises the following steps: basically, the same as example 1, except that: difference in lyophilization profile, -35 ℃ hold for 60 min; raising the temperature to-25 ℃ at-35 ℃ for 120 minutes; raising the temperature to-15 ℃ at-25 ℃ for 120 minutes; raising the temperature to-10 ℃ at-15 ℃ for 120 minutes; -10 ℃ to 5 ℃ for 60 minutes; 5 ℃ to 25 ℃ for 120 minutes.
Second, evaluation results of the preparation
1. Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet molding experiment
Purpose of the experiment: observation of the Effect of the ratio of Binder to matrix support on the moldability of lyophilized flash Release tablets
The experimental method comprises the following steps: after the sample is taken out of the box, whether the sample is cracked, collapsed or stuck at the bottom is observed by naked eyes. The samples that were acceptable in appearance were taken out after 1 month in a stability box (accelerated condition 40 ℃, RH 70%), and were visually observed for collapse.
The experimental results are as follows:
note: comparative example 1 the blister bottom was adhered and the blister was broken after removal; the samples taken from comparative examples 2 and 5 had collapsed and no accelerated test was performed.
And (4) conclusion:
(1) when the adhesive is only gelatin (comparative example 1), the prepared sample is adhered to the bottom of the aluminum-plastic blister and is not easy to take out. The adhesive is compounded by adopting gelatin and pullulan, and the prepared sample is not adhered to the aluminum-plastic bubble cap and is easy to take out.
(2) The ratio (g/ml, percent) of the adhesive (compounded by gelatin and pullulan) is 1.9-2.9 percent, and the ratio (g/ml, percent) of the mannitol is 10-12 percent, the prepared freeze-dried flash release tablet has good forming performance and no cracking and collapse phenomena, and samples are taken after the freeze-dried flash release tablet is placed for 1 month under the condition of placing accelerated test, and the samples have no shrinkage phenomena.
(3) The quick-freezing temperature of comparative example 4 was-60 deg.c, the time was extended to 60 minutes, and the prepared sample was well-formed without splintering and collapse.
(4) The freeze-drying curve of comparative example 5 was maintained for a short time in the primary drying stage, causing the sample to absorb heat too quickly, and melting occurred to cause structural collapse.
2. Determination of oral disintegration time limit of gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet
Purpose of the experiment: the influence of different adhesive and skeleton support agent ratios and freeze-drying curves on the disintegration time of the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablets.
The experimental method comprises the following steps: the disintegrating basket is fixed on a bracket and is immersed into a 1000ml cup, about 900ml of water with the temperature of 37 +/-1 ℃ is contained in the cup, and the bottom of the basket is 15 +/-1 mm below the water surface. Sample 1 tablet was placed in a disintegration basket and the time to complete disintegration and passage through a 710 μm mesh was recorded.
The experimental results are as follows:
| sample (I) | Disintegration time limit(s) |
| Example 1 | 3 |
| Example 2 | 3 |
| Example 3 | 4 |
| Example 4 | 5 |
| Comparative example 1 | / |
| Comparative example 2 | / |
| Comparative example 3 | 10 |
| Comparative example 4 | 8 |
| Comparative example 5 | / |
Note: comparative example 1 the blister bottom was adhered and the blister was broken after removal; the samples from comparative examples 2 and 5 had collapsed and no disintegration test was performed.
And (4) conclusion:
(1) the ratio (g/ml,%) of the adhesive (compounded by gelatin and pullulan) is 1.9-2.9%, the ratio (g/ml,%) of the mannitol is 10-12%, and the disintegration time of the prepared freeze-dried flash-release tablet is within 5 seconds.
(2) Comparative example 4 the prepared lyophilized flash-release tablet disintegrates slower due to the high temperature and long time of quick freezing.
Claims (10)
1. A gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet comprises 25mg of gamma-aminobutyric acid, 50-60mg of a framework supporting agent and 9.5-14.5mg of an adhesive in unit dose.
2. The lyophilized flash-release tablet of γ -aminobutyric acid containing sugar according to claim 1, wherein: the matrix support is selected from mannitol.
3. The lyophilized flash-release tablet of γ -aminobutyric acid containing sugar according to claim 1, wherein: the adhesive is composed of pullulan and gelatin, and preferably, the mass ratio of the pullulan to the gelatin is 4.5:5.0-4.5: 10.
4. The lyophilized flash-release tablet of γ -aminobutyric acid comprising sugar according to any one of claims 1 to 3, wherein: the gamma-aminobutyric acid saccharide-containing freeze-dried flash-release tablet further comprises 1-2mg of fructo-oligosaccharide in unit dose.
5. The preparation method of the gamma-aminobutyric acid containing sugar freeze-dried flash-release tablet as claimed in any one of claims 1 to 4, wherein the raw materials comprise the following substances in percentage by mass and volume: 5 percent of gamma-aminobutyric acid, 10 to 12 percent of framework supporting agent, 1.9 to 2.9 percent of adhesive and the balance of purified water.
6. The method of claim 5, wherein: the preparation method comprises the following steps:
1) dissolving the adhesive in water to obtain a feed liquid (1);
2) adding the framework supporting agent and gamma-aminobutyric acid into the feed liquid (1), stirring and dissolving completely, and then complementing the balance of water to obtain a feed liquid (2);
3) emulsifying the feed liquid (2);
4) injecting the emulsified material into a mold, quickly freezing, and freeze-drying to obtain the gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet.
7. The method of claim 6, wherein: in the step 3), the emulsification is carried out in an emulsifying machine, and the rotating speed of the emulsifying machine is 5000-15000 rpm; the emulsifying time is 5-30 min.
In the step 3), a degassing step is further included after the emulsification, preferably, the degassing is vacuum degassing for 1-20min, preferably 2-10 min.
8. The production method according to claim 6 or 7, characterized in that: in the step 4), the mould is an aluminum-plastic bubble plate;
the quick-freezing conditions are as follows: and (3) quick-freezing temperature: the temperature is between 80 ℃ below zero and 100 ℃ below zero, and the time is 5 to 10 minutes.
9. The production method according to any one of claims 6 to 8, characterized in that: in the step 4), the freeze-drying curve of the freeze-drying is as follows: keeping the temperature at 35 ℃ below zero for 2-3 h; keeping the temperature of between 35 ℃ below zero and 25 ℃ below zero for 3 to 4 hours; keeping the temperature of between 25 ℃ below zero and 15 ℃ below zero for 1 to 2 hours; keeping the temperature of between 15 ℃ below zero and 10 ℃ below zero for 1 to 3 hours; keeping the temperature at-10 to 25 ℃ for 3 to 5 hours.
10. The production method according to any one of claims 5 to 9, characterized in that:
the raw materials also comprise 0.2-0.4% of fructo-oligosaccharide, and the fructo-oligosaccharide is also added into the feed liquid (1) in the step 2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110366079.XA CN112971150B (en) | 2021-04-06 | 2021-04-06 | Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110366079.XA CN112971150B (en) | 2021-04-06 | 2021-04-06 | Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112971150A true CN112971150A (en) | 2021-06-18 |
| CN112971150B CN112971150B (en) | 2022-10-14 |
Family
ID=76339292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110366079.XA Active CN112971150B (en) | 2021-04-06 | 2021-04-06 | Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112971150B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113974143A (en) * | 2021-09-15 | 2022-01-28 | 廖佩琦 | A method for preparing fructus Rosae Normalis buccal tablet without loss of active ingredients |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893133A (en) * | 2012-12-26 | 2014-07-02 | 李和伟 | Formula and preparing method of freeze-dried excipient preparation |
| CN104367558A (en) * | 2013-08-15 | 2015-02-25 | 北京星昊医药股份有限公司 | Oseltamivir lyophilized orally-disintegrating tablets and preparation method thereof |
| CN104873458A (en) * | 2015-06-24 | 2015-09-02 | 万特制药(海南)有限公司 | Vortioxetine freeze-dried orally disintegrating tablet and preparation method thereof |
| WO2019146642A1 (en) * | 2018-01-24 | 2019-08-01 | 大原薬品工業株式会社 | METHOD FOR IMPROVING CHEMICAL STABILITY OF γ-AMINOBUTYRIC ACID DERIVATIVE- CONTAINING TABLET |
| CN112402383A (en) * | 2020-10-28 | 2021-02-26 | 北京哈三联科技有限责任公司 | Preparation method of risperidone freeze-dried tablet and product thereof |
-
2021
- 2021-04-06 CN CN202110366079.XA patent/CN112971150B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893133A (en) * | 2012-12-26 | 2014-07-02 | 李和伟 | Formula and preparing method of freeze-dried excipient preparation |
| CN104367558A (en) * | 2013-08-15 | 2015-02-25 | 北京星昊医药股份有限公司 | Oseltamivir lyophilized orally-disintegrating tablets and preparation method thereof |
| CN104873458A (en) * | 2015-06-24 | 2015-09-02 | 万特制药(海南)有限公司 | Vortioxetine freeze-dried orally disintegrating tablet and preparation method thereof |
| WO2019146642A1 (en) * | 2018-01-24 | 2019-08-01 | 大原薬品工業株式会社 | METHOD FOR IMPROVING CHEMICAL STABILITY OF γ-AMINOBUTYRIC ACID DERIVATIVE- CONTAINING TABLET |
| CN112402383A (en) * | 2020-10-28 | 2021-02-26 | 北京哈三联科技有限责任公司 | Preparation method of risperidone freeze-dried tablet and product thereof |
Non-Patent Citations (1)
| Title |
|---|
| 焦慧英等: "氯雷他定纳米混悬剂冻干口崩片的制备与质量评价", 《中国药师》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113974143A (en) * | 2021-09-15 | 2022-01-28 | 廖佩琦 | A method for preparing fructus Rosae Normalis buccal tablet without loss of active ingredients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112971150B (en) | 2022-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN112971150B (en) | Gamma-aminobutyric acid sugar-containing freeze-dried flash-release tablet and preparation method thereof | |
| CN111658740A (en) | Medicine and food dual-purpose composition capable of improving age-related macular degeneration as well as preparation method and application thereof | |
| CN105193747B (en) | A kind of lyophilized oral formulations containing agomelatine and preparation method thereof | |
| CN104784208A (en) | Deer blood crystal body and preparation method thereof | |
| CN102119939B (en) | Angiosperm bee pollen water extract for treating fatty liver and preparation method and application thereof | |
| US20170027976A1 (en) | Novel ademetionine formulations | |
| CN113069425A (en) | N-acetylneuraminic acid sugar-containing freeze-dried flash-release tablet and preparation method thereof | |
| WO2016086557A1 (en) | Vitamin d calcium composition chewing tablet and preparation method thereof | |
| US7534457B2 (en) | Hemostatic mistura of ipomoea balatas leaves, methods of preparation and use thereof | |
| CN113081981A (en) | Lactase freeze-drying flash-release tablet and preparation method thereof | |
| CN102370675A (en) | Pharmaceutical composition containing extracts of ilex latifolia as active ingredient | |
| CN1872327B (en) | Composition of medicine for treating diarrhea | |
| CN104814979A (en) | Deer blood crystal and preparation method capable of improving solubility | |
| CN109331093B (en) | Plant composition and application thereof | |
| KR101041044B1 (en) | A composition for reducing sleep induction time and prolonging sleeping time, and a method for preparing the same | |
| JP5362976B2 (en) | Blood flow improver | |
| KR101368954B1 (en) | Composition with stimulating effect, comprising the extract of medicinal plants | |
| CN104606154A (en) | Thyroid tablet composition freeze-dried tablet and preparation method thereof | |
| CN117530432B (en) | Freeze-dried and flash-released black fungus tablet and preparation method thereof | |
| CN104873541A (en) | Novel crystalline-state deer blood crystal and preparing method thereof | |
| KR101244284B1 (en) | Lquid composition powder freezing dried male silk pupa with an increased stability | |
| CN1872050B (en) | Drop pills of silymarin, and preparation method | |
| CN101194910A (en) | Dropping pills containing acegastrodine and method for preparing the same | |
| CN109820881A (en) | A kind of bitter leaves tea formulation and its preparation method and application of antigout effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220919 Address after: 061754 exhibition culture industrial park, Cangzhou Economic Development Zone, Jiefang East Road, Cangzhou Economic Development Zone, Cangzhou City, Hebei Province Applicant after: Hebei Feirui Biotechnology Co.,Ltd. Address before: 101111 room 1602, building 3, 88 Kechuang Sixth Street, Beijing Yizhuang Economic and Technological Development Zone, Daxing District, Beijing Applicant before: Beijing feiruiyanglin pharmaceutical technology research and Development Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230629 Address after: Building 3, No. 12, Wuchu Avenue, Fankou Street, Echeng District, Ezhou, Hubei Province, 436000 Patentee after: Hubei Feirui Biopharmaceutical Co.,Ltd. Address before: 061754 exhibition culture industrial park, Cangzhou Economic Development Zone, Jiefang East Road, Cangzhou Economic Development Zone, Cangzhou City, Hebei Province Patentee before: Hebei Feirui Biotechnology Co.,Ltd. |